Frontiers in immunology · 2026
Huayu Wan enhances immune checkpoint inhibitor efficacy in triple-negative breast cancer by normalizing tumor vasculature and remodeling the tumor immune microenvironment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Wenjing, You Jiafeng, Zhang Hongkai, Wu Junfan, Guo Xinran, Guan Dingkun, Yang Guowang
Аннотация
BACKGROUND: Huayu Wan (HYW), a Traditional Chinese Medicine (TCM) formulation widely used in the clinical treatment of cancer, has demonstrated anti-tumor activity and augments chemotherapy efficacy by improving intratumoral drug delivery in non-small cell lung cancer. However, its efficacy and role in enhancing the response to immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC) remain unclear.
OBJECTIVE: To study the underlying mechanisms of HYW in enhancing the efficacy of ICIs for TNBC treatment.
MATERIALS AND METHODS: In the 4T1 TNBC model, tumor growth, vascular structure/function, immune cell infiltration, angiogenic factors and effector cytokines were evaluated using ultrasound imaging, immunohistochemistry, immunofluorescence, and ELISA. HYW's effects on angiogenesis were validated via in vitro assays (HUVEC proliferation, tube formation, wound healing and transwell invasion) under normal oxygen/hypoxic conditions.
RESULTS: TCGA data and network pharmacology identified VEGFA and the PI3K-Akt/HIF-1 signaling axis as key targets of HYW. HYW significantly enhanced ICIs efficacy, with a tumor inhibition rate of 36.55% (vs. 5.01% for ICIs alone). Mechanistically, HYW: Normalized tumor vasculature: Restored the balance between proangiogenic and antiangiogenic factors (reduced VEGFA/bFGF, increased TSP-1/PF4), enhanced pericyte coverage and improved vascular maturity, and enhanced intratumoral perfusion (ultrasound imaging). Alleviated hypoxia: Inhibited HIF-1α and reduced hypoxic regions (Hypoxyprobe staining). Remodeled the TME: Promoted CD8+ T cell infiltration, increased effector cytokines (GZMB, IFN-γ, TNF-α), and inhibited CD8+ T cell exhaustion, downregulated exhaustion markers (Tim3, CD244, CD101, PD-L1). Inhibited PI3K-Akt-mTOR signaling: Reduced downstream HIF-1α/VEGFA expression, breaking the hypoxia-angiogenesis-immunosuppression cycle.
CONCLUSION: HYW enhances ICIs efficacy in TNBC by normalizing tumor vasculature and remodeling the tumor immune microenvironment (TIME), which provides a novel rationale for combining TCM with ICIs to improve TNBC treatment outcomes.
OBJECTIVE: To study the underlying mechanisms of HYW in enhancing the efficacy of ICIs for TNBC treatment.
MATERIALS AND METHODS: In the 4T1 TNBC model, tumor growth, vascular structure/function, immune cell infiltration, angiogenic factors and effector cytokines were evaluated using ultrasound imaging, immunohistochemistry, immunofluorescence, and ELISA. HYW's effects on angiogenesis were validated via in vitro assays (HUVEC proliferation, tube formation, wound healing and transwell invasion) under normal oxygen/hypoxic conditions.
RESULTS: TCGA data and network pharmacology identified VEGFA and the PI3K-Akt/HIF-1 signaling axis as key targets of HYW. HYW significantly enhanced ICIs efficacy, with a tumor inhibition rate of 36.55% (vs. 5.01% for ICIs alone). Mechanistically, HYW: Normalized tumor vasculature: Restored the balance between proangiogenic and antiangiogenic factors (reduced VEGFA/bFGF, increased TSP-1/PF4), enhanced pericyte coverage and improved vascular maturity, and enhanced intratumoral perfusion (ultrasound imaging). Alleviated hypoxia: Inhibited HIF-1α and reduced hypoxic regions (Hypoxyprobe staining). Remodeled the TME: Promoted CD8+ T cell infiltration, increased effector cytokines (GZMB, IFN-γ, TNF-α), and inhibited CD8+ T cell exhaustion, downregulated exhaustion markers (Tim3, CD244, CD101, PD-L1). Inhibited PI3K-Akt-mTOR signaling: Reduced downstream HIF-1α/VEGFA expression, breaking the hypoxia-angiogenesis-immunosuppression cycle.
CONCLUSION: HYW enhances ICIs efficacy in TNBC by normalizing tumor vasculature and remodeling the tumor immune microenvironment (TIME), which provides a novel rationale for combining TCM with ICIs to improve TNBC treatment outcomes.